Eisai To Shut Down H3 In Global R&D Restructuring

New Structure From October; New Astellas W Coast Campus

Eisai has decided to shut down its US oncology research operation H3 by September in the course of restructuring its global R&D organization. The majority of H3 employees will be laid off as Eisai Inc. and new organization DHBL absorb its functions and assets. Meanwhile another Japanese pharma firm, Astellas, builds up its US R&D footprint.

Eisai logo
79 H3 Employees Face Layoff In Global Eisai R&D Restructuring • Source: Shutterstock

Eisai Co., Ltd. has decided to shut down its US research subsidiary H3 Biomedicine Inc in September as part of a wider restructuring of its global R&D organization.

According to an official notice of layoffs published by the state of Massachusetts, where H3 is located, 79 employees will be laid off in connection with the decision

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business